What does VDPharmacy do?

VDPharmacy is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”, a code that says little about what the company actually does. Private Limited, started on 18 September 2015, 1 establishment.

What is the address of VDPharmacy?

The registered office of VDPharmacy is located at Oudenaardseweg 31, 8587 Spiere-Helkijn.

Is VDPharmacy still active?

Yes. According to the CBE (29 October 2026) VDPharmacy is active, legal situation “Normale toestand”, started on 18 September 2015.

Is VDPharmacy registered on Peppol?

Yes, VDPharmacy is registered on the Peppol network with ID 0208:0637870020.

What is the enterprise number of VDPharmacy?

The enterprise number of VDPharmacy is BE0637870020.

When was VDPharmacy founded?

VDPharmacy was founded on 18 September 2015.

Who are the directors of VDPharmacy?

According to the 2025 annual accounts, the directors of VDPharmacy are: Ellen Coudijzer, Simon Vandeputte.

Is VDPharmacy a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 September 2015; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did VDPharmacy make in 2025?

VDPharmacy recorded a loss after taxes of € 3,366 in financial year 2025.

What is the revenue of VDPharmacy?

As a small company, VDPharmacy is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 37,161.

How many employees does VDPharmacy have?

According to the 2025 annual accounts, VDPharmacy has 0 full-time equivalents (FTE).

Does VDPharmacy have a website?

Yes, VDPharmacy has a website at apotheekvandeputte.be.

VDPharmacy (Private Limited) - Spiere-Helkijn

Dossier VDPharmacy, printed on 29 October 2026 from databakkes.be/en/0637870020/vdpharmacy. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 6 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

VDPharmacy from Spiere-Helkijn, company number BE0637870020, closed financial year 2025 with a result of € -3,366 after tax. For that financial year VDPharmacy recorded a gross margin of € 37,161 and equity of € 170,901. Compared with financial year 2024, the result moved from € 35,478 to € -3,366. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.

What it is worth Healthy

€ 170,901

▼ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -3,366

▼ still € 35,478 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 7,689

▼ 38% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 152,301.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 37,767

▼ 27% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 708,064

▼ 8% vs 2024

€ 115,091 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 9,020

▲ 58% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 18,764

▼ 35% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 115,638 Gross margin 2022: € 115,638 First fiscal year in the series	€ 55,573 Gross margin 2023: € 55,573 ▼ 52% vs 2022 (€ 115,638) Unfavourable step	€ 86,239 Gross margin 2024: € 86,239 ▲ 55% vs 2023 (€ 55,573) Favourable step	€ 37,161 Gross margin 2025: € 37,161 ▼ 57% vs 2024 (€ 86,239) Unfavourable step	▼ 57%
Profit after taxes	€ 71,903 Profit after taxes 2022: € 71,903 First fiscal year in the series	€ 20,687 Profit after taxes 2023: € 20,687 ▼ 71% vs 2022 (€ 71,903) Unfavourable step	€ 35,478 Profit after taxes 2024: € 35,478 ▲ 71% vs 2023 (€ 20,687) Favourable step	€ -3,366 Profit after taxes 2025: € -3,366 ▼ € 38,844 vs 2024 (€ 35,478) Unfavourable step	▼ € 38,844
Equity	€ 128,103 Equity 2022: € 128,103 First fiscal year in the series	€ 143,790 Equity 2023: € 143,790 ▲ 12% vs 2022 (€ 128,103) Favourable step	€ 174,267 Equity 2024: € 174,267 ▲ 21% vs 2023 (€ 143,790) Favourable step	€ 170,901 Equity 2025: € 170,901 ▼ 2% vs 2024 (€ 174,267) Unfavourable step	▼ 2%
Total debts	€ 982,347 Total debts 2022: € 982,347 First fiscal year in the series	€ 1,040,685 Total debts 2023: € 1,040,685 ▲ 6% vs 2022 (€ 982,347) Unfavourable step	€ 990,238 Total debts 2024: € 990,238 ▼ 5% vs 2023 (€ 1,040,685) Favourable step	€ 984,638 Total debts 2025: € 984,638 ▼ 1% vs 2024 (€ 990,238) Favourable step	▼ 1%
Cash	€ 12,525 Cash 2022: € 12,525 First fiscal year in the series	€ 17,422 Cash 2023: € 17,422 ▲ 39% vs 2022 (€ 12,525) Favourable step	€ 12,483 Cash 2024: € 12,483 ▼ 28% vs 2023 (€ 17,422) Unfavourable step	€ 7,689 Cash 2025: € 7,689 ▼ 38% vs 2024 (€ 12,483) Unfavourable step	▼ 38%
Retained profit	€ 109,503 Retained profit 2022: € 109,503 First fiscal year in the series	€ 125,190 Retained profit 2023: € 125,190 ▲ 14% vs 2022 (€ 109,503) Favourable step	€ 155,667 Retained profit 2024: € 155,667 ▲ 24% vs 2023 (€ 125,190) Favourable step	€ 152,301 Retained profit 2025: € 152,301 ▼ 2% vs 2024 (€ 155,667) Unfavourable step	▼ 2%
Dividend	€ 5,000 Dividend 2022: € 5,000 First fiscal year in the series	€ 5,000 Dividend 2023: € 5,000 Unchanged (€ 5,000) Unchanged	€ 5,000 Dividend 2024: € 5,000 Unchanged (€ 5,000) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 5,000) Unchanged	▼ 100%
Bank debt	€ 830,384 Bank debt 2022: € 830,384 First fiscal year in the series	€ 836,917 Bank debt 2023: € 836,917 ▲ 1% vs 2022 (€ 830,384) Unfavourable step	€ 772,707 Bank debt 2024: € 772,707 ▼ 8% vs 2023 (€ 836,917) Favourable step	€ 708,064 Bank debt 2025: € 708,064 ▼ 8% vs 2024 (€ 772,707) Favourable step	▼ 8%
Balance sheet total	€ 1,110,450 Balance sheet total 2022: € 1,110,450 First fiscal year in the series	€ 1,184,475 Balance sheet total 2023: € 1,184,475 ▲ 7% vs 2022 (€ 1,110,450) Unchanged	€ 1,164,505 Balance sheet total 2024: € 1,164,505 ▼ 2% vs 2023 (€ 1,184,475) Unchanged	€ 1,155,539 Balance sheet total 2025: € 1,155,539 ▼ 1% vs 2024 (€ 1,164,505) Unchanged	▼ 1%

Key figures of VDPharmacy, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VDPharmacy?

What happened at VDPharmacy in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 1, 2026 New annual accounts for financial year 2025: loss of € 3,366 (▼ € 38,844 vs 2024). Source: NBB ↗
2023 Ellen Coudijzer became a director. NBB
Oct 1, 2015 New establishment in Spiere-Helkijn. KBO
Sep 18, 2015 Start of the company according to the CBE. KBO
2015 Simon Vandeputte became a director. NBB

In short

From € 71,903 profit in 2022 to € 3,366 loss in 2025.

Paid € 35,932 in corporate taxes since 2022.

Best year ever: 2022, with € 71,903 profit.

Paid out € 15,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Ellen Coudijzer

Simon Vandeputte

VDPharmacy

Apotheek Vandeputte 99%

Behind VDPharmacy are Ellen Coudijzer and Simon Vandeputte. It owns 99% of Apotheek Vandeputte itself.

Directors

According to the 2025 annual accounts

Ellen Coudijzer

Director

since 2023

Simon Vandeputte

Director

since 2015

Establishments

Establishment units

Physical locations of this company

Registered office

Oudenaardseweg 31

8587 Spiere-Helkijn

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

APOTHEEK VANDEPUTTE PHARMACIE same network

€ 241,700 gross margin · 2025

FREPIMON

€ 32,169 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS apotheekvandeputte.be

Technologies

BootstrapChart.jsCloudflare CDNDiviElementorFacebook PixelFont AwesomeGoogle FontsOwl CarouselPHPSwiperWPMLWooCommerceWordPressYoast SEOjQueryjQuery UIlazysizesreCAPTCHA

Hosting & Email

Email provider

Self-hosted

Hosting

CLOUDFLARENET - Cloudflare, Inc., US

DNS

Cloudflare DNS

Website info

HTTPS Ja

Languages FR, NL

Features

Webshop Blog Ads Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ IPv6

✓ Load balancing

Details

Company number: 0637.870.020
VAT number: BE 0637.870.020
Registered office: Oudenaardseweg 31, 8587 Spiere-Helkijn
Names & denominations: VDPharmacy
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 18 September 2015
Peppol: Active · Active since 3 Dec 2025
Contact: apotheekvandeputte.be [email protected] 0477 82 55 48
Activities · NACE: Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗